Is it safe to take ketorolac after a platelet‑rich plasma injection in my left knee?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ketorolac After PRP Injection: Safety Recommendations

Direct Answer

You should avoid ketorolac (and all NSAIDs) for 7–14 days after your platelet-rich plasma injection to prevent interference with the healing mechanisms that PRP is intended to promote. 1

Rationale for NSAID Avoidance

NSAIDs theoretically interfere with platelet-derived growth factor activity, which is the primary mechanism by which PRP is thought to work. 1 The growth factors released from platelets are essential for the intended therapeutic effect, and NSAIDs may blunt this biological response.

Evidence Supporting NSAID Restriction

  • 42.8% of clinical studies investigating PRP efficacy included postinjection NSAID restrictions, with durations ranging from 1 to 1800 days, though the most common restriction period was shorter-term. 2
  • 51.9% of studies excluded patients who used NSAIDs within 5 days prior to PRP injection, suggesting concern about NSAID effects on the treatment. 2
  • In vitro laboratory studies demonstrate that ketorolac combined with PRP maintains cell viability in both chondrocytes and tenocytes, suggesting ketorolac may not be directly toxic to these cells when combined with PRP. 3 However, this addresses cellular toxicity rather than the functional interference with growth factor signaling that is the primary concern.

Recommended Pain Management Alternative

Use acetaminophen (paracetamol) for pain control during the 7–14 day NSAID restriction period. 1 Acetaminophen does not interfere with platelet function or prostaglandin synthesis in the same manner as NSAIDs.

Important Context About PRP Therapy

Guideline Stance on PRP

It is important to note that major medical organizations strongly recommend against PRP for knee osteoarthritis:

  • The American College of Rheumatology/Arthritis Foundation issues a strong recommendation against PRP due to lack of standardization, heterogeneity of preparations, and insufficient evidence of clinical benefit. 1, 4
  • The American Academy of Orthopaedic Surgeons acknowledges limited evidence showing some pain reduction and functional improvement, but notes inconsistent results, particularly in severe osteoarthritis. 4
  • Medicare does not cover PRP injections for knee osteoarthritis, reflecting the guideline-based position that the procedure lacks sufficient evidence of efficacy. 5, 1

When PRP Might Be Considered

If PRP is used, it should only be considered after failure of conservative treatments (physical therapy, exercise, weight management, oral/topical NSAIDs) and injectable corticosteroids, in patients ≤80 years old with mild-to-moderate (Kellgren-Lawrence grade 0-III) osteoarthritis. 1 PRP should not be used as first-line therapy or in severe (grade IV) disease. 1

Clinical Pitfalls to Avoid

  • Do not use ketorolac or any NSAID for at least 7 days post-PRP injection, as this is the minimum restriction period recommended in guidelines. 1
  • Be aware that ketorolac carries significant bleeding risks independent of PRP considerations, including effects on platelet aggregation and increased risk when combined with anticoagulants. 6
  • Ketorolac should never be used for more than 5 days total due to gastrointestinal and renal toxicity risks. 6
  • Patients with renal impairment, elderly patients, and those on anticoagulants face heightened risks with ketorolac use. 6

References

Guideline

Guidelines on PRP Therapy and Post‑Injection NSAID Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

The effect of ketorolac tromethamine, methylprednisolone, and platelet-rich plasma on human chondrocyte and tenocyte viability.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2013

Guideline

Platelet-Rich Plasma Therapy in Orthopedic Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Platelet-Rich Plasma Therapy for Knee Pain: Guideline Recommendations and Medicare Coverage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the complications of a joint injection with Platelet Rich Plasma (PRP) therapy?
Is there evidence for platelet-rich plasma (PRP) injections in treating thumb carpometacarpal (CMC) osteoarthritis?
What are the recommendations for knee plasma injections in treating osteoarthritis?
Why should a patient with osteoarthritis and prior joint replacements receiving a platelet‑rich plasma injection in the left knee avoid ibuprofen (Nurofen) for 7–14 days, and does a single dose administered in the hospital constitute a safety problem?
What is the preparation protocol for intraarticular Platelet-Rich Plasma (PRP) injection in patients with mild to moderate degenerative osteoarthritis, including blood volume and centrifugation speed in revolutions per minute (rpm)?
In a hospitalized patient with a white blood cell count of 15 × 10⁹/L, what evaluations should be performed?
What is the acute management for a patient with an acute traumatic brain injury presenting with a hemorrhagic contusion and surrounding edema in the right frontal lobe and a skull fracture of the left parietal lobe?
Why should a patient with osteoarthritis and prior joint replacements receiving a platelet‑rich plasma injection in the left knee avoid ibuprofen (Nurofen) for 7–14 days, and does a single dose administered in the hospital constitute a safety problem?
What is the likelihood that a patient with triple‑negative breast cancer carries a germ‑line BRCA1 or BRCA2 mutation?
For an adult patient with a confirmed carbapenem‑resistant Acinetobacter baumannii infection, when is minocycline appropriate, what dosing and duration should be used (including renal adjustment), and what alternative agents are recommended if susceptibility testing is unavailable or the isolate is resistant?
In an awake adult with traumatic brain injury, intracranial hemorrhage and skull fracture, what oral medications should be started for seizure prophylaxis, analgesia, and stress‑ulcer prophylaxis, and when can chronic oral medications be resumed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.